Serum level of colony stimulating factors, Granulocyte, Monocyte and Granulocyte-Monocyte, in peripheral blood of patients with breast cancer

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 374

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ICBCMED14_117

تاریخ نمایه سازی: 21 مرداد 1398

چکیده مقاله:

Background and Aim: Colony stimulating factors (CSFs) are a group of diverse glycoproteins, which induce and regulate proliferation and differentiation of hematogenic progenitors in the bone marrow. However, increasing evidence also shows that these factors can also affect and provoke proliferation of non-hematopoietic cells including tumor cells. Therefore, we assessed Granulocyte (G-CSF), Monocyte (M-CSF) and Granulocyte-Monocyte (GM-CSF) colony stimulating factors in the serum of breast cancer (BC) patients and their association with pathological and paraclinical factors of the disease. Materials and Methods: Sixty-two untreated patients with BC as well as 54 age-sex matched controls without any history of cancer and autoimmunity in themselves and their first-degree relatives were enrolled. After assigning a consent form, 5 milliliters of peripheral blood were obtained and their serums were separated. The levels of growth factors were then checked by cytokine bead array methods. The data were analyzed by SPSS18 and P-values less than 0.05 were considered significant. Results: The mean expression of G-CSF, M-CSF and GM-CSF was measured to be 14.18 ± 13.61, 6.11 ± 5.62 and 63.48 ±83.22 in the serum of BC patients, respectively. However, there was no significant difference between patients and controls (P> 0.05), further analysis revealed that with increase in the stage of disease from I to III, the serum level of GM-CSF significantly elevated (P=0.016). Conclusion: The results collectively suggest an anti-tumorigenic role for GM-CSF in breast cancer; however, it needs to be confirmed in a more comprehensive studies with more sample size.

کلیدواژه ها:

نویسندگان

Zahra Faghih

Assistant Professor of Immunology, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Parisa Karimzadeh

General Physician, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Fatemeh Eghbali

General Physician, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Somayeh Rezaeifard

PhD in Cancer Immunology, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.